E
77.92
-0.28 (-0.36%)
| Previous Close | 78.20 |
| Open | 77.49 |
| Volume | 1,693,543 |
| Avg. Volume (3M) | 4,890,374 |
| Market Cap | 45,707,870,208 |
| Price / Earnings (TTM) | 32.20 |
| Price / Earnings (Forward) | 31.06 |
| Price / Sales | 8.18 |
| Price / Book | 4.39 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 89.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Citigroup, 21.92%) | Buy |
| Median | 75.00 (-3.75%) | |
| Low | 75.00 (Canaccord Genuity, -3.75%) | Hold |
| 75.00 (Baird, -3.75%) | Hold | |
| 75.00 (Truist Securities, -3.75%) | Hold | |
| Average | 80.60 (3.44%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 74.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 22 May 2025 | 95.00 (21.92%) | Buy | 74.79 |
| Piper Sandler | 13 May 2025 | 83.00 (6.52%) | Buy | 75.50 |
| 24 Apr 2025 | 80.00 (2.67%) | Buy | 75.13 | |
| Canaccord Genuity | 25 Apr 2025 | 75.00 (-3.75%) | Hold | 76.04 |
| Baird | 24 Apr 2025 | 75.00 (-3.75%) | Hold | 75.13 |
| Truist Securities | 11 Apr 2025 | 75.00 (-3.75%) | Hold | 69.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 May 2025 | Announcement | Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes |
| 06 May 2025 | Announcement | Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference |
| 01 May 2025 | Announcement | Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis |
| 23 Apr 2025 | Announcement | Edwards Lifesciences Reports First Quarter Results |
| 18 Apr 2025 | Announcement | Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue |
| 16 Apr 2025 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 |
| 14 Apr 2025 | Announcement | Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System |
| 31 Mar 2025 | Announcement | New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |